{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:20:27Z","timestamp":1794939627788,"version":"4.9.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Grant-In-Aid for Scientific Research"},{"DOI":"10.13039\/100016239","name":"University of Occupational and Environmental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016239","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Occupational & Environmental Health"},{"name":"Advanced Research","award":["23K15360"],"award-info":[{"award-number":["23K15360"]}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study investigated the efficacy, safety and predictive factors of belimumab (BEL) in induction therapy for patients with proliferative lupus nephritis (LN) in real-world settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with biopsy-proven ISN\/RPS class III or IV LN, with or without coexisting class V LN, who underwent standard of care (SoC), glucocorticoid (GC) and either mycophenolate mofetil or cyclophosphamide treatments were included. Participants were treated with SoC (SoC group, n\u2009=\u200932) or BEL and SoC (BEL+SoC group, n\u2009=\u200930). The primary end point was complete renal response (CRR) at 52\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline patient characteristics were not significantly different between the two groups. The 52-week retention rate of BEL was 90.0%. The BEL+SoC group showed significantly higher CRR and primary efficacy renal response achievement at 52\u2009weeks and significantly lower GC dosage, adverse events and Systemic Lupus International Collaborating Clinics damage index scores. Multivariate analysis of CRR achievement at 52\u2009weeks revealed that the lack of estimated glomerular filtration rate (eGFR) improvement at 4\u2009weeks was associated with CRR failure in the SoC group. A shorter duration (cut-off of 42\u2009days) between the start of induction therapy and addition of BEL was also related to the CRR in the BEL+SoC group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BEL, in addition to SoC, controls disease activity, reduces GC use and suppresses organ damage in case of proliferative LN. Earlier BEL induction within 6\u2009weeks may help achieve CRR in treatment-resistant cases without eGFR improvement at 4\u2009weeks after induction therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae495","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T19:48:53Z","timestamp":1726602533000},"page":"1930-1939","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-1233","authenticated-orcid":false,"given":"Hidenori","family":"Sakai","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-3881","authenticated-orcid":false,"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-8454","authenticated-orcid":false,"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-9263","authenticated-orcid":false,"given":"Satoshi","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Hanami","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-8826","authenticated-orcid":false,"given":"Shunsuke","family":"Fukuyo","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Laboratory and Transfusion Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-145X","authenticated-orcid":false,"given":"Ippei","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0212-172X","authenticated-orcid":false,"given":"Masanobu","family":"Ueno","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-1317","authenticated-orcid":false,"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Todoroki","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-4104","authenticated-orcid":false,"given":"Naoaki","family":"Ohkubo","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2586-246X","authenticated-orcid":false,"given":"Masashi","family":"Funada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2025040212135587200_keae495-B1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1756-185X.13817","article-title":"State-of-the-art treatment of systemic lupus erythematosus","volume":"23","author":"Tanaka","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2025040212135587200_keae495-B2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025040212135587200_keae495-B3","doi-asserted-by":"crossref","first-page":"103404","DOI":"10.1016\/j.autrev.2023.103404","article-title":"From systemic lupus erythematosus to lupus nephritis: the evolving road to targeted therapies","volume":"22","author":"Xipell","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025040212135587200_keae495-B4","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212135587200_keae495-B5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025040212135587200_keae495-B6","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1093\/rheumatology\/keab953","article-title":"Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus","volume":"61","author":"Miyazaki","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212135587200_keae495-B7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025040212135587200_keae495-B8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025040212135587200_keae495-B9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active, Systemic Lupus Erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025040212135587200_keae495-B10","doi-asserted-by":"crossref","first-page":"102729","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort","volume":"124","author":"Gatto","year":"2021","journal-title":"J Autoimmun"},{"key":"2025040212135587200_keae495-B11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000529675","article-title":"Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China","volume":"9","author":"Tan","year":"2023","journal-title":"Kidney Dis (Basel)"},{"key":"2025040212135587200_keae495-B12","first-page":"kead707","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study","volume":"25","author":"Sishi","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212135587200_keae495-B13","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025040212135587200_keae495-B14","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025040212135587200_keae495-B15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025040212135587200_keae495-B16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/rheumatology\/keu343","article-title":"Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus","volume":"54","author":"Ishizaki","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212135587200_keae495-B17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"2025040212135587200_keae495-B18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025040212135587200_keae495-B19","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2025040212135587200_keae495-B20","first-page":"377","article-title":"Accurately describing changes in disease activity in Systemic Lupus Erythematosus","volume":"27","author":"Gladman","year":"2000","journal-title":"J Rheumatol"},{"key":"2025040212135587200_keae495-B21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann Intern Med"},{"key":"2025040212135587200_keae495-B22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology"},{"key":"2025040212135587200_keae495-B23","doi-asserted-by":"crossref","first-page":"e208-219","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025040212135587200_keae495-B24","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025040212135587200_keae495-B25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"2025040212135587200_keae495-B26","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21drives expansion and plasma cell differentiation of autoreactive CD11chiTbet+ B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"2025040212135587200_keae495-B27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"key":"2025040212135587200_keae495-B28","doi-asserted-by":"crossref","first-page":"e000962","DOI":"10.1136\/lupus-2023-000962","article-title":"Differential expression of IFN-\u03b1, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis","volume":"10","author":"Nawata","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025040212135587200_keae495-B29","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/rheumatology\/keac528","article-title":"SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis","volume":"62","author":"Itotagawa","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212135587200_keae495-B30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fmed.2020.00085","article-title":"Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission","volume":"7","author":"You","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025040212135587200_keae495-B31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025040212135587200_keae495-B32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025040212135587200_keae495-B33","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"2025040212135587200_keae495-B34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025040212135587200_keae495-B35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025040212135587200_keae495-B36","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the maintain nephritis trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae495\/60741773\/keae495.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1930\/60741773\/keae495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1930\/60741773\/keae495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T18:34:15Z","timestamp":1743618855000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/1930\/7759631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,17]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae495","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,9,17]]}}}